Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68071-3553

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68071-3553). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3553 6)

Label for Divalproex Sodium 250 mg delayed-release tablets from NuCare Pharmaceuticals, Inc. The package contains 60 tablets, oval-shaped and biconvex orange with imprint '797' in black ink on one side. The label includes dosing instructions to take one tablet every 8 hours and storage information for controlled temperatures 68-77°F.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart labeled Figure 1 comparing the percentage outcomes between PBO (placebo) and DVPX (Divalproex Sodium) across two studies: Study 1 (YMRS) and Study 2 (MRS). The chart shows DVPX with higher percentages (60% and 58%) compared to PBO (26% and 29%).*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Kaplan-Meier plot depicting % reduction in CPS rate for Divalproex Sodium (DVPX) versus placebo across % of patients. The y-axis shows % reduction in CPS rate, indicating improvement or worsening from -100% to 100%. The x-axis represents the reversed cumulative % of patients from 100 to 0. Solid line is DVPX; dashed line is placebo.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A line graph comparing the percentage reduction in CPS rate for patients treated with high dose and low dose of Divalproex Sodium. The x-axis shows the percentage of patients from 100 to 0, and the y-axis shows percentage reduction in CPS rate from -100% to 100%, with annotations indicating improvement, no change, and worsening.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Bar chart titled 'Mean 4-week Migraine Rates' comparing migraine rates between Placebo and Divalproex Sodium (DVPX) groups in two studies. Study 1 shows higher migraine rates for Placebo than DVPX. Study 2 similarly shows higher migraine rates for Placebo compared to DVPX, with both studies illustrating reduced migraine rates for Divalproex Sodium groups.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of Divalproex Sodium, showing the molecular arrangement of its organic and sodium components in polymeric form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.